Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT03680794
Recruiting Not applicable

Soluble Cluster of Differentiation 160 (sCD160) in Sera and Intra-ocular Fluids: Association With Ischaemic Retinopathies

NCT03680794 · tracked via the Priya Life Science France tracker
Sponsor
CHU de Reims
Phase
Not applicable
Started
2018-06-27
Last updated
2026-04-30

Condition(s) studied

Diabetic RetinopathyRetinal Vein Occlusion

Investigational drug(s) / intervention(s)

sampling of ophthalmic liquid

sampling of ophthalmic liquid: aqueous sampling for patients with cataract surgery or vitreous sampling for patients with posterior segment surgery

Study summary

CD160 represents a new angiogenic factor as its specific engagement by an agonist monoclonal antibody directed against human CD160 reduced angiogenesis of endothelial cells with a distinct mechanism from current angiogenic therapies that target the VEGF/VEGF-R pathway. A soluble form of CD160, sCD160, has been found to be highly expressed in the vitreous and the sera of patients with severe diabetic retinopathies, and can now be dosed with help of an ELISA test.

The investigators aim to evaluate the association between ischaemic retinopathies (patients with or without) and sCD160 concentrations in the vitreous, the aqueous humour and the serum.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
inclusion criteria : * over 18 years old * with social security affiliation * willing to participate this study non-inclusion criteria : * any prior (3 months) or concomitant treatment with anti-VEGF therapy, corticosteroids, or immunosuppressive agents * any history of previous vitreoretinal surgery, ocular tumor, severe ocular trauma, severe intraocular, periocular infection, inflammation, or radiation * any serious allergy to the fluorescein sodium for injection in angiography * any history of previous systemic anti-VEGF treatment * any history of inflammatory or auto-immune disease * any active extraocular inflammation or infection in the last 4 weeks before surgery exclusion criteria : * Patients with C-reactive protein CRP \> 10mg/mL (serum sampling during surgery)

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Chu Reims Reims France Recruiting

More CHU de Reims trials in France

Prevalence and Consequences of Antiphospholipid Syndrome in Patients Aged 65 and Over With Ischemic Strokes (IS) Recruiting
Ventilator Associated Pneumonia Multiplex PCR for Anti-Infective Regimens Recruiting
Use of a New Method for the Microbiological Diagnosis of Severe Corneal Infection Recruiting
Evaluation of the Efficacy of the Addition of Magnesium Sulfate to Morphine on the Occurrence of Acute Urinary Retention Following Epidural Anesthesia for Cesarean Section. Recruiting
Microsurgical Robot-assisted Corneal Transplant Recruiting

Other trials for the same condition

Performance of the Electroretinogram, Performed and Interpreted by an Advanced Practice Nurse, in the Screening for Diabetic Retinopathy. Recruiting
A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products Active, not recruiting
Screening for Diabetic RETINopathy Using a Non-mydriatic Retinograph Funduscope in Occupational MEDicine Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03680794 on ClinicalTrials.gov ↗ ← All trials in France